OakChart

ClearPoint Neuro Inc

CLPTHealthcare·Medical Devices·USA·Micro·NASD·Nov 11 • 3:59 PM ET

9.17+0.40 (4.56%)
2026-11-11 23:25 CET
Market cap
281.12 USD m
Revenue, TTM
45.49 USD m
Net income, TTM
-36.13 USD m
Free cash flow, TTM
-33.22 USD m
EPS diluted, TTM
-1.21
P/E
-
Compare

Price

CLPT against its 20, 50 and 200-day averages
2050200earnings
10.0015.0020.003.4M6.9MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CLPTclose 9.1720-day 9.4950-day 11.48200-day 12.759.1752w high52w low

53.3% under the 52-week high of 19.63 on 29 Jun 2026. 52-week low 8.27 on 10 Apr 2026. Last 15 sessions, 44.7% high to low

Volume 0.66× normal · the line is the 50-bar volume average

Profile

CLPT
52-week range, 8% of the way up
8.2719.63

ClearPoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

IndexRUT
Employees172
IPOMay 21, 2012
Beta1.38
ATR, 14d0.77
Rel volume0.66
Short float15.10%
Insider own11.27%
Inst own44.34%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap293.94M
Enterprise Value321.46M
Income-36.13M
Sales45.49M
Book/sh0.85
Cash/sh1.44
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees172
IPOMay 21, 2012

Ratios

P/E-
Forward P/E-
PEG-
P/S6.46
P/B10.78
P/C6.37
P/FCF-
EV/EBITDA-
EV/Sales7.07
Quick Ratio5.77
Current Ratio6.76
Debt/Eq2.70
LT Debt/Eq2.70
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.21
EPS next Y-0.92
EPS next Q-0.23
EPS this Y-29.44%
EPS next Y21.03%
EPS next 5Y1.50%
EPS past 3/5Y-9.90% -16.08%
Sales past 3/5Y21.62% 23.58%
EPS Y/Y TTM-46.56%
Sales Y/Y TTM32.51%
EPS Q/Q-16.22%
Sales Q/Q36.27%
EarningsOct 28 AMC
EPS/Sales Surpr.23.81% -1.83%

Ownership

Insider Own11.27%
Insider Trans-2.91%
Inst Own44.34%
Inst Trans1.87%
ROA-41.75%
ROE-167.52%
ROIC-35.86%
Gross Margin60.03%
Oper. Margin-70.56%
Profit Margin-79.43%
SMA20-3.39%
SMA50-20.13%
SMA200-28.11%
Trades-

Technical

Shs Outstand32.05M
Shs Float28.44M
Short Float15.10%
Short Ratio6.46
Short Interest4.29M
52W High19.63 -53.29%
52W Low8.27 10.88%
Volatility9.09% 7.37%
ATR (14)0.77
RSI (14)42.18
Beta1.38
Rel Volume0.66
Avg Volume665.10K
Volume440,280

Performance

Perf Week-9.74%
Perf Month-6.52%
Perf Quarter-40.53%
Perf Half Y-24.77%
Perf YTD-32.97%
Perf Year-47.30%
Perf 3Y105.61%
Perf 5Y-44.46%
Perf 10Y129.25%
Recom1.00
Target Price21.50
Prev Close8.77
Price9.17
Change %4.56%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
May 08, 2026ResumedSStifelBuy$16+74.5%
Jul 25, 2024ResumedRB. Riley SecuritiesBuy$10+9.1%
Oct 24, 2023InitiatedSStifelBuy$8-12.8%
Feb 16, 2023ResumedRB. Riley SecuritiesBuy$14+52.7%
Apr 05, 2022ResumedRB. Riley SecuritiesBuy$15+63.6%
Mar 18, 2021InitiatedLLake StreetBuy$32+249.0%
Jul 17, 2020InitiatedBB. Riley FBRBuy$8-12.8%

Peers

Mkt cap
TickerCompanyMkt cap
MDTMedtronic Plc129.98B
IARTIntegra Lifesciences Holdings Corp1.15B
PROFProfound Medical Corp287.55M
NPCENeuroPace Inc429.73M
ZBHZimmer Biomet Holdings Inc20.34B
GMEDGlobus Medical Inc9.99B
NMTCNeuroOne Medical Technologies Corp7.31M
SYKStryker Corp121.36B
LIVNLivaNova PLC5.01B
BSXBoston Scientific Corp65.41B

Insider trading

latest 14 of 27
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
BURNETT JOSEPHCEO and PresidentSep 02 '26Option Exercise3.4712,51743,434130,720Sep 03 06:22 PM
BURNETT JOSEPHCEO and PresidentJun 29 '26Option Exercise2.5020,00050,000136,842Jul 01 06:43 PM
BURNETT JOSEPHCEO and PresidentJun 29 '26Sale19.3820,000387,600116,842Jul 01 06:43 PM
JOSEPH BURNETTDirectorJun 29 '26Proposed Sale18.4820,000369,600Jun 29 04:42 PM
BURNETT JOSEPHCEO and PresidentJun 17 '26Option Exercise2.5060,000150,000176,842Jun 22 04:05 PM
BURNETT JOSEPHCEO and PresidentJun 17 '26Sale17.7960,0001,067,400116,842Jun 22 04:05 PM
BURNETT JOSEPHCEO and PresidentJun 17 '26Sale17.941,84333,063191,388Jun 22 04:05 PM
JOSEPH M BURNETT TRUSTAffiliate of DirectorJun 17 '26Proposed Sale13.341,84324,586Jun 17 04:33 PM
JOSEPH BURNETTDirectorJun 17 '26Proposed Sale13.3460,000800,400Jun 17 04:31 PM
Richards Timothy T.DirectorJun 04 '26Option Exercise10.005005,00087,698Jun 08 04:30 PM
Richards Timothy T.DirectorJun 01 '26Sale12.175,41565,90187,198Jun 02 04:30 PM
TIMOTHY RICHARDSDirectorJun 01 '26Proposed Sale12.175,14562,612Jun 01 04:07 PM
PASCAL E. GIRINDirectorMay 29 '26Proposed Sale12.5466,679836,455May 29 05:24 PM
Klein Matthew B.DirectorMay 21 '26Sale11.5916,000185,44046,935May 26 04:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
KOMPState Street SPDR S&P Kensho New Economies Composite ETFAUM: 2.46B
XHEState Street SPDR S&P Health Care Equipment ETFAUM: 160.14M
IWCiShares Micro-Cap ETFAUM: 1.22B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
ITOTiShares Core S&P Total U.S. Stock Market ETFAUM: 95.28B

News

latest 14 of 200
  • ClearPoint Neuro's Q3 Operating Rebound Meets Another Guidance Trim, Margin Slide And First ATM Draw (Earnings Whispers) +8.98%
  • ClearPoint Neuro Reports Third Quarter 2026 Results (ACCESSWIRE)
  • ClearPoint Neuro Needs A Revenue Rebound To Back Its Pivot Toward Drug Delivery (Earnings Whispers)
  • ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 (ACCESSWIRE) -5.81%
  • ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update (InvestorsHub) -23.12%
  • ClearPoint Neuro Reports Second Quarter 2026 Results (ACCESSWIRE) -16.29%
  • ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel (ACCESSWIRE)
  • Earnings To Watch: ClearPoint Neuro Inc (CLPT) Q2 2026 -- GF Value Sees 28% Upside (GuruFocus.com)
  • ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026 (ACCESSWIRE)
  • ClearPoint Neuro Shares Jump as FDA Progress for UniQure Therapy Highlights Platform Value (InvestorsHub) +26.01%
  • ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint (ACCESSWIRE) +6.43%
  • ClearPoint Neuro Inc (CLPT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth (GuruFocus.com)
  • ClearPoint Neuro Reports First Quarter 2026 Results (ACCESSWIRE)
  • ClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global Footprint (ACCESSWIRE)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-28-0.240-0.315-0.24012.0812.302
2026Q22026-08-03-0.380-0.287-0.37610.8812.733
2026Q12026-05-13-0.320-0.273-0.32312.1311.973
2025Q42026-03-17-0.260-0.200-0.27110.4010.052
2025Q32025-11-06-0.210-0.200-0.2078.869.602
2025Q22025-08-12-0.210-0.200-0.2079.229.202
2025Q12025-05-13-0.220-0.159-0.2178.498.213
2024Q42025-02-26-0.200-0.164-0.1957.778.233
2024Q32024-11-07-0.180-0.173-0.1808.127.773
2024Q22024-08-07-0.160-0.197-0.1617.867.333
2024Q12024-05-07-0.160-0.190-0.1637.606.993
2023Q42024-03-12-0.180-0.203-0.1886.806.533
2023Q32023-11-09-0.200-0.250-0.1955.766.733
2023Q22023-08-08-0.290-0.190-0.2875.955.902
2023Q12023-05-11-0.230-0.190-0.2285.435.001
2022Q42023-03-01-0.180-0.200-0.1795.205.202

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-0.560--0.5647.35-
2019FY-0.420--0.42111.22-
2020FY-0.430-0.460-0.42812.8312.41
2021FY-0.690-0.680-0.69516.3016.30
2022FY-0.680-0.705-0.68020.6020.60
2023FY-0.900-0.913-0.89823.9623.70
2024FY-0.700-0.672-0.70031.3931.83
2025FY-0.900-0.830-0.90036.9736.60
2026FY--1.165--48.50
2027FY--0.920--55.80
2028FY--0.860--64.40
2029FY--0.770--76.20

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-2920113.4012.9013.90
2026Q4S2026-10-2820013.6512.9014.40
2026Q4S2026-10-1820013.6512.9014.40
2026Q4S2026-08-2720213.6512.9014.40
2026Q4S2026-08-0430313.6012.9014.40
2026Q4S2026-07-2830014.6314.3014.90
2026Q4S2026-06-0131014.6314.3014.90
2026Q4S2026-05-1431114.6314.3014.90
2026Q4S2026-05-0730214.5314.3014.80
2026Q4S2026-03-1820214.4014.3014.50
2026Q4S2026-02-0820015.5515.2015.90
2026Q4S2026-01-2121015.5515.2015.90
2026Q4S2025-11-2522015.5515.2015.90
2026Q4S2025-11-1121014.0012.1015.90

Estimate history

EPS, annual-0.93-0.564-0.421-0.428-0.695-0.68-0.898-0.7-0.902-1.2109
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.18-0.195-0.217-0.207-0.207-0.271-0.323-0.376-0.241
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual7.387.35311.21712.82916.29920.55123.95531.3936.97145.49
Period201720182019202020212022202320242025TTM
Sales, quarterly8.1227.7718.4859.2158.86110.4112.12810.8812.075
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual10.69411.01815.23517.04823.66624.57924.65327.61729.36932.051
Period201720182019202020212022202320242025MRQ
Shares, quarterly27.58927.61727.9828.42428.42829.36929.98730.50332.051
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue45.4936.9731.3923.9520.5516.3012.8311.227.35
Cost of Goods Sold Incl. D&A18.1814.3512.2710.347.025.013.713.832.43
Gross Profit27.3122.6219.1213.6113.5311.299.127.384.92
Selling, General and Administrative Excl. Other59.4146.7938.8636.0629.8624.6615.3411.9810.17
Research and Development16.4113.9012.3911.7110.898.984.692.922.31
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-32.10-24.16-19.73-22.45-16.33-13.37-6.22-4.59-5.25
Interest Expense4.942.390.52-0.080.971.440.960.98
Unusual Expense0.000.000.000.00-----0.06
Net Income Before Taxes-36.16-25.48-18.90-22.09-16.43-14.41-6.78-5.54-6.16
Income Taxes-0.030.060.010.000.000.000.000.000.00
Consolidated Net Income-36.13-25.54-18.91-22.09-16.43-14.41-6.78-5.54-6.16
Net Income From Continuing Operations-36.13-25.54-18.91-22.09-16.43-14.41-6.78-5.54-6.16
Net Income-36.13-25.54-18.91-22.09-16.43-14.41-6.78-5.54-6.16
EPS (Recurring)-1.17-0.90-0.70-0.90-0.68-0.69-0.43-0.42-0.57
EPS (Basic, Before Extraordinaries)-1.21-0.90-0.70-0.90-0.68-0.69-0.43-0.42-0.56
EPS (Diluted)-1.21-0.90-0.70-0.90-0.68-0.69-0.43-0.42-0.56
EBITDA-27.14-21.93-17.83-20.99-15.55-12.68-5.67-4.34-5.14
Non-Operating Income (Expense)0.881.071.350.36-0.02-0.060.880.010.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.606.465.466.084.132.081.090.801.23
Price To Sales Ratio8.3210.4813.246.979.9714.2719.635.632.33
Gross Margin60.0361.1960.9256.8365.8469.2771.0965.8366.91
Operating Margin-70.56-65.36-62.87-93.70-79.47-82.05-48.48-40.95-71.37
Net Margin-79.43-69.08-60.25-92.21-79.97-88.41-52.86-49.39-83.82
Shares Outstanding32.0529.3727.6224.6524.5823.6717.0515.2411.02
Market Capitalization281.12281.12424.25167.17207.98265.24268.0672.9917.30

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue12.0710.8812.1310.418.869.218.487.77
Cost of Goods Sold Incl. D&A5.224.384.584.013.263.663.353.01
Gross Profit6.856.507.556.405.605.565.134.76
Selling, General and Administrative Excl. Other13.1916.7516.0313.4510.8811.2411.2910.37
Research and Development4.024.634.523.243.453.833.383.33
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.33-10.24-8.48-7.04-5.28-5.68-6.16-5.60
Interest Expense1.451.411.380.700.540.08--
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-7.46-11.38-9.54-7.78-5.88-5.81-6.01-5.39
Income Taxes-0.00-0.040.010.000.010.030.020.00
Consolidated Net Income-7.46-11.34-9.55-7.79-5.89-5.84-6.03-5.39
Net Income From Continuing Operations-7.46-11.34-9.55-7.79-5.89-5.84-6.03-5.39
Net Income-7.46-11.34-9.55-7.79-5.89-5.84-6.03-5.39
EPS (Recurring)-0.24-0.38-0.32-0.27-0.21-0.21-0.22-0.20
EPS (Basic, Before Extraordinaries)-0.24-0.38-0.32-0.27-0.21-0.21-0.22-0.20
EPS (Diluted)-0.24-0.38-0.32-0.27-0.21-0.21-0.22-0.20
EBITDA-4.71-8.87-7.37-6.19-4.85-5.05-5.83-5.13
Non-Operating Income (Expense)0.310.280.32-0.03-0.06-0.050.150.22
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.491.791.751.561.601.791.511.70
Price To Sales Ratio8.3212.736.6210.6318.0410.0410.2213.53
Gross Margin56.7559.7962.2461.5263.2060.2960.4861.28
Operating Margin-52.44-94.15-69.90-67.68-59.54-61.64-72.63-72.11
Net Margin-61.78-104.20-78.76-74.79-66.48-63.34-71.02-69.31
Shares Outstanding32.0530.5029.9929.3728.4328.4227.9827.62
Market Capitalization281.12535.01269.94406.96619.43337.48328.55424.25

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments45.9220.1023.1437.4954.1120.105.703.109.29
Short Term Receivables7.265.363.942.672.341.881.091.230.95
Inventories8.366.867.919.304.943.243.242.112.31
Other Current Assets1.911.041.181.420.510.240.360.210.19
Total Current Assets63.4533.3636.1750.8861.8925.4610.386.6512.75
Net Property, Plant & Equipment11.055.094.952.702.783.060.820.380.27
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets21.390.001.041.030.270.350.00--
Deferred Tax Assets3.140.00-------
Other Assets1.850.730.490.880.640.650.720.820.88
Total Assets100.8939.1942.6655.4965.5829.5211.937.8613.90
Short Term Debt Incl. Current Port. of LT Debt0.690.560.420.560.510.390.110.002.00
Accounts Payable1.261.340.390.270.430.300.970.500.76
Other Current Liabilities8.818.466.615.963.822.512.751.511.64
Total Current Liabilities10.7710.357.436.794.753.203.832.014.40
Long Term Debt57.543.0113.5211.4311.7823.732.353.482.92
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities3.500.00-------
Other Liabilities1.070.440.540.390.260.211.160.860.75
Total Liabilities72.8713.8021.4918.6016.7927.147.346.358.07
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity28.0225.3921.1736.8948.792.384.591.515.83
Total Shareholders Equity28.0225.3921.1736.8948.792.384.591.515.83
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity28.0225.3921.1736.8948.792.384.591.515.83
Total Liabilities & Stockholders Equity100.8939.1942.6655.4965.5829.5211.937.8613.90
Book Value Per Share0.950.920.861.502.060.140.300.140.55
Tangible Book Value Per Share0.230.920.821.462.050.120.300.140.55
Full-Time Employees1721151071082827213834
Price to Book Ratio10.3114.636.945.205.44113.9615.9411.453.91
Return on Assets-36.47-46.22-45.01-27.15-30.31-32.73-56.00-56.66-67.30
Return on Equity-95.64-81.24-76.09-38.37-56.33-194.78-181.70-167.95-282.59
Return on Invested Capital-29.85-66.60-63.68-34.02-23.79-25.98-79.87-123.48-81.94
Quick Ratio5.122.563.806.1311.986.951.862.272.37
Current Ratio5.893.224.877.5013.027.962.713.312.90

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-36.13-25.54-18.91-22.09-16.43-14.41-6.78-5.54-6.16
Depreciation4.962.241.901.460.780.690.550.250.11
Other Funds (Non Cash)9.709.196.667.273.782.381.091.531.81
Funds from Operations-21.52-14.11-10.35-13.36-11.88-11.34-5.14-3.76-4.25
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-10.65-9.811.40-0.36-4.29-1.68-2.660.91-0.38
Cash from Operating Activities-32.17-23.93-8.95-13.72-16.17-13.02-7.81-2.85-4.63
Capital Expenditures-1.04-0.52-0.28-1.05-1.15-0.17-0.48-0.16-0.06
Net Assets From Acquisitions1.141.140.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.0010.00-9.590.000.000.000.00
Purchase of Investments0.000.000.000.00-21.590.000.000.000.00
Sale Or Maturity of Investments0.000.000.0010.0012.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.090.61-0.288.95-10.74-0.17-0.48-0.16-0.06
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock23.553.9516.610.510.7447.470.387.740.51
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock23.553.9516.610.510.7447.470.387.740.51
Proceedsfrom Stock Options0.003.2616.150.510.4847.010.007.350.00
Issuance or Reduction of Debt, Net19.4348.09-10.000.000.000.0022.32-2.14-2.00
Change in Long Term Debt19.4348.09-10.000.000.000.0022.32-2.140.00
Issuance of Long Term Debt19.4348.090.000.000.000.0025.150.000.00
Reduction of Long Term Debt0.000.00-10.000.000.000.00-2.84-2.140.00
Net Financing Active Other Cash Flow-2.19-1.86-0.42-0.21-0.34-0.600.000.000.00
Other Financing Activities Uses-2.19-1.86-0.42-0.21-0.34-0.60-0.000.00
Cash from Financing Activities40.7950.186.190.300.4146.8822.695.60-1.49
Net Change in Cash8.7126.87-3.04-4.47-26.4934.0114.402.59-6.19
Free Cash Flow-33.22-24.45-9.22-14.44-16.42-13.19-7.85-2.86-4.69
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments46.1829.3635.5945.9238.2241.54
Short Term Receivables9.089.369.447.265.264.85
Inventories9.778.818.578.366.586.29
Other Current Assets1.681.201.271.911.271.31
Total Current Assets66.7148.7354.8863.4551.3353.99
Net Property, Plant & Equipment24.3215.6316.0011.058.078.16
Total Investments and Advances0.930.000.000.000.180.00
Intangible Assets19.8820.3920.8921.39--
Deferred Tax Assets---3.14--
Other Assets0.891.991.651.850.780.72
Total Assets112.7386.7493.42100.8960.3662.87
Short Term Debt Incl. Current Port. of LT Debt0.200.190.230.690.350.33
Accounts Payable1.062.152.331.260.721.53
Other Current Liabilities8.617.976.928.816.985.54
Total Current Liabilities9.8710.319.4810.778.057.40
Long Term Debt73.5063.7563.3557.5435.4035.12
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.300.320.353.50--
Other Liabilities1.791.581.391.071.030.60
Total Liabilities85.4675.9774.5872.8744.4843.13
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity27.2710.7818.8428.0215.8719.74
Total Shareholders Equity27.2710.7818.8428.0215.8719.74
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity27.2710.7818.8428.0215.8719.74
Total Liabilities & Stockholders Equity112.7386.7493.42100.8960.3662.87
Book Value Per Share0.850.350.630.950.560.69
Tangible Book Value Per Share0.23-0.32-0.070.230.560.69
Full-Time Employees---172--
Price to Book Ratio10.3128.399.5424.5031.3716.71
Return on Assets-41.75-46.21-47.08-36.47-46.03-38.50
Return on Equity-167.52-226.52-149.72-95.64-103.13-85.68
Return on Invested Capital-7.40-15.21-11.62-9.10-11.49-10.64
Quick Ratio5.773.874.885.125.566.45
Current Ratio6.764.735.795.896.377.30

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-7.46-11.34-9.55-7.79-5.89-5.84
Depreciation1.621.371.110.850.430.63
Other Funds (Non Cash)1.932.862.692.232.382.46
Funds from Operations-3.93-7.14-5.75-4.71-3.09-2.75
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.180.12-2.22-7.37-0.040.20
Cash from Operating Activities-5.11-7.01-7.97-12.08-3.12-2.55
Capital Expenditures-0.14-0.21-0.65-0.05-0.20-0.09
Net Assets From Acquisitions0.000.000.001.140.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.14-0.21-0.651.09-0.20-0.09
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock22.071.000.150.330.003.68
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock22.071.000.150.330.003.68
Proceedsfrom Stock Options0.000.000.000.000.003.34
Issuance or Reduction of Debt, Net0.000.000.0019.4328.650.00
Change in Long Term Debt0.000.000.0019.4328.650.00
Issuance of Long Term Debt0.000.000.0019.4328.650.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-1.99-0.20-28.6528.30
Other Financing Activities Uses0.000.00-1.99-0.200.00-0.36
Cash from Financing Activities22.071.00-1.8419.560.0031.98
Net Change in Cash16.82-6.23-10.468.57-3.3229.33
Free Cash Flow-5.25-7.23-8.61-12.13-3.32-2.64

Revenue breakdown

Biologics And Drug Delivery - Services And License Fees2024: 11.70M 2025: 11.70M
Biologics and Drug Delivery - Disposable Products2024: 5.61M 2025: 7.34M
Capital Equipment and Software - Services2024: 1.06M 2025: 1.41M
Capital Equipment and Software - Systems and Software Products2024: 2.74M 2025: 1.69M
Neurosurgery Navigation And Therapy2024: 10.29M 2025: 14.83M
United States2024: 31.39M 2025: 36.97M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3015.10%4.3M28.4M682.90K
2026-10-1517.10%4.6M27.1M657.45K
2026-09-3017.59%4.8M27.1M617.96K
2026-09-1515.99%4.3M27.1M742.71K
2026-08-3115.52%4.2M27.0M720.46K
2026-08-1416.64%4.5M27.0M742.42K
2026-07-3114.41%3.9M27.0M720.39K
2026-07-1513.90%3.7M26.6M704.34K
2026-06-3016.18%4.3M26.6M714.85K
2026-06-1518.50%4.9M26.6M582.60K
2026-05-2917.84%4.7M26.6M741.70K
2026-05-1516.90%4.5M26.6M749.05K
2026-04-3018.56%4.9M26.6M742.26K
2026-04-1517.66%4.7M26.4M792.35K
2026-03-3117.28%4.4M25.7M829.39K
2026-03-1316.71%4.3M25.7M820.08K
2026-02-2712.92%3.3M25.7M674.16K
2026-02-1313.50%3.5M25.7M664.01K
2026-01-3012.90%3.3M25.7M795.71K
2026-01-1512.34%3.2M25.8M791.73K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.504.607.609.9811.4571.000.000.947-0.0880.002
call5.002.106.104.689.27114.000.000.875-0.0880.003
call6.001.155.200.007.7230.000.000.838-0.0820.004
call7.500.302.705.503.4049330.000.755-0.0690.004
call9.000.001.300.702.1545.000.000.582-0.0540.006
call10.000.001.000.312.40855764.000.481-0.0770.006
call11.000.000.950.252.7582130.000.418-0.0870.006
call12.500.000.500.501.95550460.000.187-0.0420.004
call14.000.000.400.102.99765.000.000.245-0.0750.004
call15.000.000.800.152.9881,2620.000.205-0.0690.004
call16.000.001.750.003.2190.000.000.195-0.0720.004
call17.500.000.700.053.5291870.000.184-0.0760.004
call19.000.002.150.003.8030.000.000.175-0.0790.004
call20.000.000.250.252.8851,4840.000.065-0.0300.002
call22.500.002.150.313.2043000.000.061-0.0310.002
call25.000.002.150.153.4801410.000.057-0.0320.002
call30.000.000.100.054.1601,0510.000.072-0.0420.002
call35.000.002.150.054.3201790.000.049-0.0350.001
call40.000.000.750.054.1962460.000.027-0.0210.001
put2.500.002.150.009.9850.000.00-0.053-0.0870.002
put5.000.001.950.225.2541800.00-0.125-0.0870.003
put6.000.002.150.004.1150.000.00-0.162-0.0810.004
put7.500.000.700.302.6641820.00-0.246-0.0670.005
put9.000.001.000.501.3981160.00-0.418-0.0530.006
put10.000.551.501.151.7544860.00-0.519-0.0760.006
put11.001.102.900.002.9920.000.00-0.582-0.0860.006
put12.502.704.304.123.4372620.00-0.726-0.0660.005
put14.002.906.900.005.9120.000.00-0.783-0.0630.004
put15.004.007.904.226.21116.000.00-0.795-0.0670.004
put16.005.008.900.006.4810.000.00-0.805-0.0700.004
put17.506.5010.408.826.84421.000.00-0.816-0.0740.004
put19.008.9011.900.007.1630.000.00-0.825-0.0770.004
put20.009.0012.906.257.3560.000.00-0.935-0.0270.002
put22.5011.5015.406.997.7890.000.00-0.939-0.0290.002
put25.0014.5017.3011.707.0710.000.00-0.943-0.0290.002
put30.0019.5022.9017.008.7760.000.00-0.948-0.0310.002
put35.0023.9027.9014.949.2760.000.00-0.951-0.0310.001
put40.0028.9032.9027.009.6930.000.00-0.973-0.0170.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-03SCHEDULE 13G/ASEC
2026-10-2810-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-288-KCurrent report2026-10-28SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-08-12SCHEDULE 13G/ASEC
2026-08-04SCHEDULE 13G/ASEC
2026-08-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-07-27SCHEDULE 13G/ASEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-17144Filing for proposed sale of securities under Rule 144.SEC
2026-06-17144Filing for proposed sale of securities under Rule 144.SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-01144Filing for proposed sale of securities under Rule 144.SEC
2026-05-29144Filing for proposed sale of securities under Rule 144.SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-06001.55M4
2026-0500242.15K2
2026-040000
2026-030000
2026-0200302.66K1
2026-0100368.22K2
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.7.94%
MAK CAPITAL ONE LLC7.92%
VANGUARD CAPITAL MANAGEMENT LLC4.11%
STATE STREET CORP2.72%
GEODE CAPITAL MANAGEMENT, LLC2.43%
UBS Group AG1.78%
Lane Generational LLC1.45%
MILLENNIUM MANAGEMENT LLC1.19%
BROWN ADVISORY INC1.09%
Pekin Hardy Strauss, Inc.0.91%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.85%
iShares Russell 2000 ETF2.46%
VANGUARD EXTENDED MARKET INDEX FUND1.17%
Fidelity Small Cap Index Fund1.03%
iShares Russell 2000 Growth ETF0.88%
VANGUARD RUSSELL 2000 INDEX FUND0.53%
Fidelity Extended Market Index Fund0.49%
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF0.41%
iShares Micro-Cap ETF0.32%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF0.30%

OakChart. CLPT. Cached 15 minutes.